Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 2Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Malignant mesenchymal tumor 1Liposarcoma, Myxoid 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1

Interventions

lentiviral minigene vaccine of COVID-19 coronavirus 1cediranib 1brostallicin 1Temozolomide 1Radiation Dose Hypofractionation 1Doxorubicin 1Diathermy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Sarcoma, Alveolar Soft Part × brostallicin × Clear all
NCT00410462 2014-08-08

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Unknown
118 enrolled
GynecologicSarcoma

Malignant mesenchymal tumor, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡